Antisoma to amend ACCEDE phase III study of AS1413
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex
Scripps Research Scientists Illuminate Structure of Circulating Lung Cancer Cells
To keep up to date with news from this category use our
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
CAMBRIDGE, Mass. November 4, 2009 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the...
BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEXGM-CSF IN THE JOURNAL OF CLINICAL ONCOLOGY
Woburn, MA, November 2, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2...
YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
MISSISSAUGA, ON, Nov. 2 , 2009 - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at...
Cancer trials and good manufacturing practice
October 30, 2009--An article in Friday's issue of the Danish medical journal 'Dagens Medicin' accuses the Danish Medicines Agency of delaying the development of new cancer medicine. The specific case involves an...
Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal Cancer Patients to Benefit from State-of-the-Art RapidArc and Novalis Tx Installations
PORTO, Portugal, Oct. 30, 2009-- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR) by the...
CEL-SCI Corporation Strengthens Balance Sheet Through Receipt of $10 Million From Warrant Exercises
VIENNA, Va., Oct. 26 -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common...
Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
October 26, 2009 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has...
Bayer and Onyx Initiate Phase III Trial of Nexavar
Berlin, October 23, 2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
SOUTH SAN FRANCISCO, Calif. & NEW YORK-- October 23, 2009-- Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated...
PRIMA BIOMED SECURES JAPANESE PATENT FOR CANCER VAC
October 22, 2009--Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that its subsidiary company, Cancer Vac Pty Ltd, has received a Decision to Grant from the Japanese Patent Office...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22 -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
SAN DIEGO, Oct 22, 2009 -- Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze(TM) technology (rHuPH20, recombinant human...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Endocyte presents data on EC145 in treatment of ovarian cancer at the 16th annual meeting of the European Society of Gynaecologic Oncology
WEST LAFAYETTE, Ind. -October 21, 2009 - Endocyte, Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for...
Antigenics Announces a Negative Vote From the CHMP on Oncophage
London, UK -- October 21, 2009 -- Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company...
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...
Alfacell Corporation Announces Closing of $3.25 Million Private Placement
SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross proceeds through the sale...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22-- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
New Preclinical Data confirms PG545 as a promising clinical candidate for cancer
Brisbane, Australia, 14 October 2009: Progen Pharmaceuticals Limited (ASX:PGL; NASDAQ: PGLA) today announced that new preclinical data on PG545, a dual antiangiogenic and anti-heparanase inhibitor, will be presented at...
Eckert & Ziegler awards grants to young researchers in nuclear medicine
Berlin, October 14, 2009. This year's travel grants from Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) have been awarded to five nuclear medicine scientists from Germany, Italy, Poland and...
European Medicines Evaluation Agency Grants Orphan Drug Designation to ARQ 197 for Treatment of Soft Tissue Sarcoma
WOBURN, Mass.--Oct. 14, 2009-- ArQule, Inc. (NASDAQ: ARQL) today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue...
ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG
Tokyo, Japan -- October 13, 2009 -- Oncolys BioPharma Inc. (headquarters: Tokyo; President and CEO: Yasuo Urata) announced today that it has entered into a strategic alliance and license agreement with Astellas Pharma...
SRI International Awarded a Department of Defense "Laboratory-Clinical Transition" Grant to Advance SRI's Novel Anticancer Agents for Prostate Cancer Treatment
MENLO PARK, Calif. --October 13, 2009--SRI International, an independent, nonprofit research and development organization, announced today that it has been awarded a $1.55M U.S. Department of Defense/Prostate Cancer...
Scripps Research Scientists Illuminate Structure of Circulating Lung Cancer Cells
LA JOLLA, CA, October 13, 2009 - Most cancer-related deaths are caused by metastases - the spread of cancer to other parts of the body - and tumor cells that circulate in the bloodstream are generally understood to be...
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
The Institute of Cancer Research and The Royal Marsden Honoured with Oncology Award
October 09, 2009 -- A programme to improve cancer pain management has won The Institute of Cancer Research (ICR) in collaboration with The Royal Marsden NHS Foundation Trust recognition for the Best Professional...
MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial
Martinsried/Munich, October 9, 2009. MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) has successfully completed patient recruitment into its randomized Phase II trial of EndoTAG(TM)-1 for the treatment of triple...
Ipsen acquires exclusive marketing rights of BLI-800 from Braintree for colonic cleansing before colonoscopy
Braintree (Massachusetts, United States) and Paris (France), 9 October 2009 - Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group and Braintree Laboratories, Inc., a US-based...
Antisoma to amend ACCEDE phase III study of AS1413
London, UK, and Cambridge, MA: 08 October 2009 Antisoma announces that, following discussions with FDA and trial investigators, it plans to amend the primary endpoint in the ACCEDE study of AS1413. The ACCEDE study is...
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
BERKELEY, Calif. - October 8, 2009 -- Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating...
HEAD AND NECK TRIAL UPDATE
October 08, 2009--Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to announce that a second hospital has commenced recruitment of patients for the Company's Phase I CAVATAK(TM) trial for the treatment of Head and...
In JCO, Danusertib results of a Phase 1 trial. Phase 2 in patients with lung cancer and other solid tumors ongoing.
Nerviano Italy, 8 October 2009 - Nerviano Medical Sciences today announced a publication in the peer-reviewed scientific journal, Journal of Clinical Oncology (*), of the first clinical trial performed in man in...
American Shared Hospital Services Updates Progress in the Development of a Proton Therapy Center at Long Beach Memorial Hospital
San Francisco, CA, October 8, 2009 -- AMERICAN SHARED HOSPITAL SERVICES (AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent...
ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates
LOS ANGELES, CA -October 08, 2009 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers,...
Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open for Enrollment at Duke Comprehensive Cancer Center
NEW YORK, October 8, 2009 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or...
Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000
London, United Kingdom, 08 October, 2009 - Spirogen Limited (Spirogen), the UK-based developer of DNA-interactive drugs, today announced that the private equity firm Celtic Therapeutics Holdings LP will invest up to $15...
Ipsen and Spirogen redesign their collaboration for the development of SJG-136 (now SG2000)
Paris (France), and London (United Kingdom), 8 October 2009 - Ipsen (Euronext : FR0010259150; IPN) and Spirogen Ltd. announced today that the parties have entered into a new agreement superseding their 2003 contractual...
Two Hutchinson Center scientists receive a total of $16.7 million for collaborative stem cell research
SEATTLE -- October 7, 2009 -- The National Heart, Lung and Blood Institute has awarded a total of $16.7 million to Irwin Bernstein, M.D., and Beverly Torok-Storb, Ph.D., both members of the Clinical Research Division at...
Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
FARMINGDALE, N.Y., October 7, 2009 -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other...
Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex
NATICK, Mass., Oct. 6 -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(
Cold Spring Harbor Laboratory receives more than $22 million in federal stimulus grants
Cold Spring Harbor, NY -October 6, 2009 Cold Spring Harbor Laboratory (CSHL) has been awarded more than $22 million in grants by the National Institutes of Health (NIH) and the National Science Foundation (NSF) under...
Epigenomics AG Launches its Epi proColon Product in Europe - the First Ever In Vitro Diagnostic Blood Test for Colorectal Cancer Early Detection
October 06, 2009 -- Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic (IVD) products for cancer, today launched the...
Ad Hoc Announcement pursuant of
October 06, 2009 -- Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, today announced, that it launched in Europe a CE-marked, in vitro diagnostic blood test for early detection of colorectal...
mtm laboratories Extends Series C Financing Round by EUR 7 Million Bringing Total to EUR 39 Million (USD 57 Million)
Heidelberg, Germany; October 5, 2009- mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis,...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
SAN DIEGO---Oct. 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical...
Cancer Research UK and Astrazeneca to Accelerate Biomarker Research
Birmingham, Monday 5th October, 2009 --- AstraZeneca is to double its investment in Cancer Research UK's biomarker research in an effort to better understand how drugs behave in early stage clinical trials.
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
PHILADELPHIA, PA, October 5, 2009 - GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the...
ARQULE PROVIDES CLINICAL UPDATE ON ARQ 197
WOBURN, Mass.--Oct. 5, 2009ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.
DIAGNOCURE SIGNS DISTRIBUTION AGREEMENT IN THE UK FOR ITS COLORECTAL CANCER TEST
QUEBEC CITY, October 5, 2009 DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement...
SCIENTIST EMBARKS ON REVOLUNTIONARY RESEARCH STUDY
October 5, 2009 -- LONDON, Ontario - Imagine facing a terminal illness uncertain and alone. For young women living in Yemen, a country located on the Arabian Peninsula in Southwest Asia and many other developing...
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
MISSISSAUGA, ON, Oct. 5, 2009 - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
SAN DIEGO-- October 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic...
$16 million in federal stimulus funding establishes Seattle as a hub of comparative-effectiveness research in cancer
SEATTLE -- October 5, 2009 -- Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington School of Public Health have been selected to lead four projects...
Allos Therapeutics Announces U.S. Availability of FOLOTYN(TM) (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma
WESTMINSTER, Colo.--Oct. 5, 2009-- Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that FOLOTYN(TM) (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug...
Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial
BOTHELL, Wash.----Oct. 5, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its...
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
GAITHERSBURG, Md., Oct. 5, 2009-- Schering-Plough Corp. (NYSE: SGP) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to...
PrimeraDx Awarded 4th Patent Covering STAR Technology
MANSFIELD, Mass. - October 5, 2009 -- PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene...
Federal stimulus funding channels more than $40 million to Fred Hutchinson Cancer Research Center
SEATTLE -- October 5, 2009 -- Scientists at Fred Hutchinson Cancer Research Center have been awarded 60 research grants totaling nearly $40.4 million under the American Recovery & Reinvestment Act of 2009. The totals...
GENVEC RECEIVES NATIONAL CANCER INSTITUTE GRANT TO EXPAND CANCER PROGRAM
GAITHERSBURG, MD - September 30, 2009 - GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the...
BSD Medical Corporation Sells Hyperthermia System to University of California, San Francisco Medical Center
SALT LAKE CITY, September 29, 2009--BSD Medical Corporation (NASDAQ:BSDM, www.BSDMedical.com) announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia...
Sanofi-aventis launches major insulin research program in partnership with the international scientific community
Paris, France - September 29, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the company's action plan to provide methodologically robust research that will contribute to the scientific resolution...
Video: Celsion Corporation Initiates Enrollment Awareness Program for Pivotal Phase I/II DIGNITY Trial of ThermoDox(R) in Patients with Recurrent Chest Wall (RCW) Breast Cancer
COLUMBIA, Md., Sept 28, 2009 -- Celsion Corporation (Nasdaq: CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox(R) in...
Vical Presents Positive Preclinical Results with Vaxfectin(R)-Formulated, Peptide-based Cancer Vaccine
BOSTON, Sept. 24, 2009-- Vical Incorporated (Nasdaq:VICL) announced today the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin(R)...
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
BERLIN- September 24, 2009 -Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy...
Philips and Celsion Advance Development of ThermoDox(R) and MR-Guided HIFU
ANDOVER, Mass. & COLUMBIA, Md., Sep 23, 2009 -- Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox(R) in...
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
BERLIN-- September 23, 2009-- According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX
BSD Medical Reports News Briefing at Europe's Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients
SALT LAKE CITY, September 22, 2009--. BSD Medical Corporation (NASDAQ:BSDM) reports that significant and "medical practice changing" clinical study results were the subject of a news briefing at Europe's largest cancer...
New phase II data presented at ECCO 15 - 34th ESMO Congress reinforces exciting potential of Algeta's Alpharadin as a new treatment for bone metastases in cancer patients
Oslo, Norway, 22 September 2009 - Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announces that new clinical data from three phase II clinical trials with Alpharadin have been presented at the joint 15th...
Data Safety Monitoring Board Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
COLUMBIA, Md., Sep 21, 2009 -- Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board ("DSMB") has reviewed the safety data from the first group of patients enrolled in its pivotal...
Algeta to present new clinical data from three phase II trials with Alpharadin at ECCO 15 - 34th ESMO Congress
Oslo, Norway, 17 September 2009 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that new clinical data from three phase II clinical trials with Alpharadin comprising its phase II efficacy and...
Celsion's ThermoDox(R) Study for RCW Breast Cancer Aired on ABC and CBS Affiliate Stations
COLUMBIA, Md., Sep 16, 2009-- Celsion Corporation (NASDAQ:CLSN) announced today the Company's DIGNITY clinical trial evaluating the use of ThermoDox(R) in combination with hyperthermia for the treatment of Recurrent...
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
SOUTH SAN FRANCISCO, Calif., Sept 15, 2009 -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that 320 evaluable events (patient deaths) have occurred in its pivotal Phase 3 SPEAR (Study of Picoplatin...
Detailed Data From Vical's TransVax(TM) CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC
SAN DIEGO, Sept. 14, 2009 -- Vical Incorporated (Nasdaq:VICL) announced today that detailed results from a four-month interim analysis in an ongoing Phase 2 trial of the company's TransVax(TM) therapeutic...
FDA Clears a Test for Ovarian Cancer
September 11, 2009--The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and...
Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath's Phase III Clinical Trial
NEW YORK, Sept. 11 -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the Data and Safety...
Vical Receives $2.5 Million Payment for Funding of Allovectin-7(r) Phase 3 Trial
SAN DIEGO, Sept. 8, 2009 -- Vical Incorporated (Nasdaq:VICL) today announced the receipt from AnGes MG, Inc., of a $2.5 million installment payment for the company's ongoing Allovectin-7(r) Phase 3 metastatic melanoma...
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway
Oslo, Norway, 27 August 2009--Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received a government grant of up to USD 1.1 mill (NOK 6.9 mill) to accelerate the Phase II clinical programme with Intravenous...
Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia
Brookline,MA , June 25, 2008 -- Tarix Phamaceuticals announced that it has received FDA approval to begin a Phase II clinical trial of TXA127 for the prevention of chemotherapy induced thrombocytopenia. The trial will...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
